+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07314216

Phase II Study of Firmonertinib with Radiotherapy for Stage III Unresectable Lung Adenocarcinoma Harboring Rare EGFR Mutations

Led by Hunan Cancer Hospital · Updated on 2026-07-08

15

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of firmonertinib, a third-generation EGFR tyrosine kinase inhibitor EGFR-TKI, with definitive radiotherapy in patients who have Stage III unresectable lung adenocarcinoma with uncommon EGFR mutations. This Phase II, single-arm study aims to assess the progression-free survival PFS and safety of this treatment approach, addressing the limited benefit of current standard therapies for this patient group, particularly as immunotherapy shows modest effects in EGFR-mutant cases. Participants will receive oral firmonertinib at a dose of 160 mg once daily continuously until disease progression or unacceptable toxicity occurs, combined with definitive thoracic radiotherapy delivered over about 6 weeks using advanced radiation techniques. The treatment includes an induction phase of firmonertinib alone for 10-12 weeks, a concurrent radiotherapy phase lasting 6-7 weeks, and a consolidation phase of firmonertinib monotherapy thereafter. Radiotherapy targets the primary tumor and involved lymph nodes with strict safety protocols. During the study, participants will be closely monitored through imaging and clinical evaluations to measure tumor response and progression. The primary outcome is progression-free survival assessed up to 30 months after treatment completion. Secondary outcomes include overall survival, objective response rate, disease control rate, and safety assessments including adverse events. Follow-up will continue for up to 60 months to gather long-term data on treatment effects and patient health.

CONDITIONS

Brief Title

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

Research Team

H

Huai Liu

X

Xingxiang Pu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here